title: Effect of multiple intravenous doses of lanicemine (AZD6765) on the pharmacokinetics of midazolam in healthy subjects.
abstract: The objectives of the present study were to evaluate safety and tolerability as well as the effects of multiple doses of lanicemine on the pharmacokinetics of a CYP3A substrate, midazolam. A total of 46 healthy volunteers were enrolled in the open-label, fixed-sequence, nonrandomized study. All volunteers received an oral dose of 5 mg of midazolam alone or after 6 days of 150 mg daily intravenous infusion of lanicemine. Lanicemine reached a plasma Cmax of 1.51 μg/mL after 150 mg daily dosing to steady state. The geometric mean CL, Vss, and t1/2 of lanicemine were 8.1 L/h, 122.0 L, and 10.4 hours, respectively. The geometric least-squares mean ratios and 90% confidence intervals for midazolam AUC0- ∞ , and Cmax were within the 80% to 125% limits when lanicemine plus midazolam treatment was compared with midazolam alone, demonstrating that daily dosing with 150 mg of lanicemine for 6 days had no effect on CYP3A activity. Comprehensive physiologically based pharmacokinetic modeling using in vitro and in silico findings also indicated lanicemine would have little impact on the pharmacokinetics of CYP3A substrate, such as midazolam. In addition, lanicemine and midazolam administered alone or in combination were generally safe and well tolerated.
authors.affiliation: Quantitative Clinical Pharmacology, AstraZeneca LP, Wilmington, DE, USA.
authors.forename: Khanh H
authors.initials: KH
authors.lastname: Bui
authors.affiliation: Quantitative Clinical Pharmacology, AstraZeneca LP, Waltham, MA, USA.
authors.forename: Diansong
authors.initials: D
authors.lastname: Zhou
authors.affiliation: Quantitative Clinical Pharmacology, AstraZeneca LP, Wilmington, DE, USA.
authors.forename: Felix
authors.initials: F
authors.lastname: Agbo
authors.affiliation: DMPK of Infection Innovative Medicine, AstraZeneca LP, Waltham, MA, USA.
authors.forename: Jian
authors.initials: J
authors.lastname: Guo
mesh_terms: D000759:Adjuvants, Anesthesia / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008874:Midazolam / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D010627:Phenethylamines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: C585977:AZD6765; D000759:Adjuvants, Anesthesia; D000928:Antidepressive Agents; D010627:Phenethylamines; D011725:Pyridines; D008874:Midazolam
keywords: drug-drug interaction; lanicemine; midazolam